Objective To assess the outcome of patients with advanced ovarian cancer (OC) who were treated without surgery, having received upfront chemotherapy and no interval debulking surgery (IDS). Methods Retrospective analysis of medical and chemotherapy records of consecutive patients with OC between 2005 and 2013 at UCL Hospitals London, UK who received neoadjuvant chemotherapy (NACT) was then found to be unsuitable for IDS following review by the multidisciplinary team. Results Eighty-three patients (18%) out of 467 receiving NACT did not undergo IDS. Median age was 70 years (range 33–88); out of these 83 patients, 43 (51.8%) presented with stage IV disease. Forty-three of these 83 patients received carboplatin and paclitaxel (CP) (51.8%) and 37 received carboplatin alone (C) (44.6%); 3 patients (3.6%) received other platinum-based combinations. Reasons for not proceeding to surgery were: poor response to chemotherapy after 3–4 cycles of NACT (61/83, 73.5%); comorbidities (12/83, 14.5%); patient decision (4/83, 4.8%). Six patients (7.2%) received < 3 cycles of NACT due to a worsening clinical condition. The median overall survival (OS) for patients not undergoing IDS was 18 months (95% CI 10–20 months). Forty-four of 83 patients (53%) received > 2 lines of chemotherapy. In a univariate analysis CP, age < 70 years, and absence of comorbidities were factors influencing OS. In a multivariate analysis only having received CP remained independently associated with OS (HR 0.49, 95% CI 0.29–0.84). Conclusions Chemotherapy alone can provide reasonable disease control in patients unsuitable for IDS and CP should be used if possible.

Marchetti, C., Kristeleit, R., Mccormack, M., Mould, T., Olaitan, A., Widschwendter, M., Macdonald, N., Ledermann, J. A., Outcome of patients with advanced ovarian cancer who do not undergo debulking surgery: A single institution retrospective review, <<GYNECOLOGIC ONCOLOGY>>, n/a; 144 (1): 57-60. [doi:10.1016/j.ygyno.2016.11.001] [http://hdl.handle.net/10807/203875]

Outcome of patients with advanced ovarian cancer who do not undergo debulking surgery: A single institution retrospective review

Marchetti, Claudia;
2017

Abstract

Objective To assess the outcome of patients with advanced ovarian cancer (OC) who were treated without surgery, having received upfront chemotherapy and no interval debulking surgery (IDS). Methods Retrospective analysis of medical and chemotherapy records of consecutive patients with OC between 2005 and 2013 at UCL Hospitals London, UK who received neoadjuvant chemotherapy (NACT) was then found to be unsuitable for IDS following review by the multidisciplinary team. Results Eighty-three patients (18%) out of 467 receiving NACT did not undergo IDS. Median age was 70 years (range 33–88); out of these 83 patients, 43 (51.8%) presented with stage IV disease. Forty-three of these 83 patients received carboplatin and paclitaxel (CP) (51.8%) and 37 received carboplatin alone (C) (44.6%); 3 patients (3.6%) received other platinum-based combinations. Reasons for not proceeding to surgery were: poor response to chemotherapy after 3–4 cycles of NACT (61/83, 73.5%); comorbidities (12/83, 14.5%); patient decision (4/83, 4.8%). Six patients (7.2%) received < 3 cycles of NACT due to a worsening clinical condition. The median overall survival (OS) for patients not undergoing IDS was 18 months (95% CI 10–20 months). Forty-four of 83 patients (53%) received > 2 lines of chemotherapy. In a univariate analysis CP, age < 70 years, and absence of comorbidities were factors influencing OS. In a multivariate analysis only having received CP remained independently associated with OS (HR 0.49, 95% CI 0.29–0.84). Conclusions Chemotherapy alone can provide reasonable disease control in patients unsuitable for IDS and CP should be used if possible.
2017
Inglese
Marchetti, C., Kristeleit, R., Mccormack, M., Mould, T., Olaitan, A., Widschwendter, M., Macdonald, N., Ledermann, J. A., Outcome of patients with advanced ovarian cancer who do not undergo debulking surgery: A single institution retrospective review, <<GYNECOLOGIC ONCOLOGY>>, n/a; 144 (1): 57-60. [doi:10.1016/j.ygyno.2016.11.001] [http://hdl.handle.net/10807/203875]
File in questo prodotto:
Non ci sono file associati a questo prodotto.

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/10807/203875
Citazioni
  • ???jsp.display-item.citation.pmc??? ND
  • Scopus 12
  • ???jsp.display-item.citation.isi??? 10
social impact